Compare RDCM & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDCM | MDWD |
|---|---|---|
| Founded | 1985 | 2000 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.2M | 238.5M |
| IPO Year | 1997 | 2014 |
| Metric | RDCM | MDWD |
|---|---|---|
| Price | $13.41 | $18.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $18.00 | ★ $37.50 |
| AVG Volume (30 Days) | 76.8K | ★ 93.0K |
| Earning Date | 11-12-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.57 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $68,901,000.00 | $20,932,000.00 |
| Revenue This Year | $18.86 | $15.89 |
| Revenue Next Year | $11.39 | $25.33 |
| P/E Ratio | $20.99 | ★ N/A |
| Revenue Growth | ★ 17.27 | 6.15 |
| 52 Week Low | $9.88 | $14.14 |
| 52 Week High | $15.98 | $22.51 |
| Indicator | RDCM | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 55.76 |
| Support Level | $12.81 | $18.55 |
| Resistance Level | $13.88 | $19.05 |
| Average True Range (ATR) | 0.41 | 0.57 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 62.06 | 66.25 |
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.